about
Synthetic DNA vaccine strategies against persistent viral infectionsImmunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus.Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesEscalating threat from tuberculosis: the third epidemicNYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectorsInteraction between unrelated viruses during in vivo co-infection to limit pathology and immunityEnhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 proteinVaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens.Expression of Aleutian mink disease parvovirus capsid proteins by a recombinant vaccinia virus: self-assembly of capsid proteins into particlesVaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice.Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.
P2860
Q27016078-32CBFCEB-CC5D-44E2-B20F-EDCD6BC1F9FCQ33608668-526AB1D9-DF39-4314-8862-89A49EAA802AQ33637231-E9B78D7C-DEE3-4D4B-8F2E-42B8ABB26C86Q33821288-FB3A2925-7910-4846-BD22-B0A73BB843E3Q35519418-0CC62A92-5F1F-4458-924B-A5BE02084528Q35677112-ABBF83EA-159D-49CF-86B3-8F78B6450F27Q35914427-7157365E-B18B-454C-8136-ECF598336C89Q36053149-92E074F8-A0F1-4DCF-AB56-254A85B51BD9Q36137980-8DCC88B9-1C5A-40C1-8247-38226F65536AQ36643929-4E02CE34-65AB-4B65-874D-299E88E497E2Q36646890-77D86FDA-364D-4B14-99F7-1F6DFBE68F09Q36697529-18C6C61A-209B-4B48-837C-C75EB22E4D32Q36953142-D568706F-F21E-4C82-9580-1E552A3DFC7AQ39824887-B68676B9-643C-4117-8ACF-57632C125662
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Poxvirus-based vectors as vaccine candidates.
@en
type
label
Poxvirus-based vectors as vaccine candidates.
@en
prefLabel
Poxvirus-based vectors as vaccine candidates.
@en
P2093
P1476
Poxvirus-based vectors as vaccine candidates
@en
P2093
P577
1990-01-01T00:00:00Z